This is a new application for a training program in immune recognition of cancer cells at Ohio State University Medical Center. Fourteen scientists at the Ohio State University (OSU) will be joining forces to train the next generation of tumor immunologists, with strong emphasis on T-cell tumor interaction and novel approaches for tumor immunotherapy. In many regards, immune recognition of cancer falls in the t w ilight zone of autoimmunity and transplantation immunity. A full understanding of the nature of tumor immunity requires insights into these disciplines. Therefore, senior scientists with insights in both areas are also included into this program. Collectively, the training faculty will have overlapping expertise, ranging from innate to adaptive immunity, from fundamental mechanisms of immune recognition of cancer cells to up-to-date technology in immunotherapy, and from small animal cancer models to clinical trials, thus providing trainees with a rich academic environment in cancer immunology. In addition, the training program will strengthen the preexisting interactions among OSU faculty in this area, while fostering intellectual exchange of scientific ideas and expertise among trainees. The trainees will participate in several seminar series, including a monthly distinguished lecture series on Cancer Immunology, weekly Comprehensive Cancer Center medical grand-rounds, a weekly immunology seminar, and a biweekly Immunology Research in Progress that is to be presented exclusively by trainees.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA090223-05
Application #
7007709
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2002-07-25
Project End
2008-05-31
Budget Start
2005-12-01
Budget End
2008-05-31
Support Year
5
Fiscal Year
2006
Total Cost
$161,090
Indirect Cost
Name
Ohio State University
Department
Pathology
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Willis, William L; Wang, Linan; Wada, Takuma Tsuzuki et al. (2018) The proinflammatory protein HMGB1 is a substrate of transglutaminase-2 and forms high-molecular weight complexes with autoantigens. J Biol Chem 293:8394-8409
Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509
Latchana, Nicholas; Abrams, Zachary B; Howard, J Harrison et al. (2017) Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. Bioinform Biol Insights 11:1177932217694837
Farren, Matthew R; Hennessey, Rebecca C; Shakya, Reena et al. (2017) The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther 16:417-427
Talbert, Erin E; Yang, Jennifer; Mace, Thomas A et al. (2017) Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Mol Cancer Ther 16:344-356
Yang, Jennifer; Farren, Matthew R; Ahn, Daniel et al. (2017) Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opin Ther Targets 21:485-498
Markowitz, Joseph; Wang, Jiang; Vangundy, Zach et al. (2017) Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Sci Rep 7:15424
Pyter, Leah M; Suarez-Kelly, Lorena P; Carson 3rd, William E et al. (2017) Novel rodent model of breast cancer survival with persistent anxiety-like behavior and inflammation. Behav Brain Res 330:108-117
Suarez-Kelly, Lorena P; Campbell, Amanda R; Rampersaud, Isaac V et al. (2017) Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy. Nanomedicine 13:909-920

Showing the most recent 10 out of 70 publications